Platelet-rich plasma therapy (PRP)has become one of the most talked-about procedures in hair loss medicine over the past decade. It is offered at clinics worldwide, its prices vary enormously, and patient reports of its effectiveness are mixed. The clinical evidence is more substantive than critics suggest and less definitive than proponents claim. This article explains what PRP is, how it is supposed to work, what the best available evidence shows, and who is most likely to benefit.
What Is PRP?
Platelet-rich plasma is produced by drawing a patient's own blood and processing it in a centrifuge to concentrate the platelet fraction. Platelets are small blood cells that release growth factors as part of the wound healing process. These growth factors include platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-b), insulin-like growth factor 1 (IGF-1), and epidermal growth factor (EGF).
When PRP is injected into the scalp, the released growth factors are thought to stimulate follicle activity, promote angiogenesis (new blood vessel growth), and activate hair follicle stem cells.
PRP uses a patient's own growth factors to stimulate follicle activity. It does not introduce any foreign substances — the active components come from the patient's own blood.
The Proposed Mechanisms
The mechanisms whereby which PRP is proposed to act on hair follicles are biologically plausible and supported by laboratory evidence.
PDGF stimulates follicle dermal papilla cells and promotes angiogenesis, increasing blood supply to the follicle. VEGF similarly promotes new blood vessel formation around the follicle. IGF-1 has been shown to prolong the anagen phase in laboratory studies. EGF promotes keratinocyte proliferation relevant to hair shaft production.
A 2014 laboratory study found that PRP meaningfully increased the proliferation of dermal papilla cells and up-regulated the expression of FGF-7, VEGF, and beta-catenin — signaling factors associated with anagen induction. This provides mechanistic support for the clinical observations.
The proposed mechanisms for PRP are not speculative — they are grounded in documented growth factor biology. Whether the concentrations delivered clinically are sufficient to produce consistent hair growth is the clinical question.
What the Clinical Evidence Shows
The PRP literature is characterized by a large number of small studies with variable methodology, differing PRP preparation protocols, and heterogeneous patient populations. This makes direct comparison across studies difficult. With that caveat in place, the trend in the evidence is positive.
A 2017 randomized controlled trial enrolled 45 patients with androgenetic alopecia in a split-scalp design. Each patient's scalp was divided in half, with PRP injections on one side and saline on the other. After three monthly sessions, the PRP-treated side showed meaningfully greater hair density, hair shaft diameter, and anagen rate.
A 2018 meta-analysis examined 19 published studies on PRP for androgenetic alopecia including 460 patients. It found meaningful increases in hair density, hair count, and follicle caliber across studies, with a good safety profile.
A 2021 systematic review and meta-analysis of 26 studies found that PRP consistently outperformed control conditions in hair density improvement. The mean improvement in hair density was about 33 hairs per cm² compared to control.
The cumulative evidence favors PRP for androgenetic alopecia. Effect sizes are meaningful, and the safety profile is good. The evidence is not as strong as for finasteride or minoxidil — the trials are smaller and more variable — but the direction is consistent.
Variability in Outcomes
Despite the generally positive trend, there is significant variability in PRP outcomes across patients and across clinics. This variability is driven by several factors:
Preparation protocol: The concentration of platelets, the presence or absence of leukocytes (white blood cells), the method of activation, and the processing time all affect the growth factor composition of the final product. No standardized protocol exists.
Injection technique: Depth of injection, distribution pattern, and volume injected vary by practitioner.
Patient characteristics: PRP appears to work better in patients with earlier-stage androgenetic alopecia, good platelet health (not in patients on anticoagulants or with platelet dysfunction), and no significant concurrent health conditions.
Number of sessions: Most published protocols use three initial sessions, four to six weeks apart, followed by maintenance sessions at 6 to 12-month intervals. Single-session results are generally weaker than the full protocol.
The variation in PRP outcomes is largely attributable to protocol differences rather than the treatment itself being fundamentally inconsistent. Standardized preparation and technique produce more reliable results.
PRP vs. Standard Medical Treatments
PRP is generally considered an add-on to, not a replacement for, medical treatments. Head-to-head comparisons with minoxidil show PRP producing comparable results to topical minoxidil in some studies, with the combination of the two outperforming either alone.
PRP does not suppress the hormonal process driving androgenetic alopecia. For this reason, using PRP without a DHT-suppressing agent leaves the primary driver of loss untreated.
The most evidence-supported use of PRP in androgenetic alopecia is as an add-on to finasteride or dutasteride and minoxidil — adding growth factor stimulation to a protocol already addressing DHT.
PRP is a complement to medication treatment, not a substitute for it. The combination of DHT suppression plus minoxidil plus PRP addresses more pathways simultaneously than any single modality. Safety Profile
PRP is autologous, derived from the patient's own blood, which eliminates the risk of allergic reaction or rejection. Side effects are related to the injection procedure: temporary pain or discomfort at the injection sites, mild scalp redness or swelling, and occasional bruising. These typically resolve within 48 to 72 hours.
Serious adverse events are very rare and are generally related to injection technique rather than the PRP itself.
PRP has an excellent safety profile as an autologous treatment. The main adverse effects are injection-site reactions, which are transient. Summary
PRP concentrates a patient's own growth factors and injects them into the scalp to stimulate follicle activity. The biological mechanisms are plausible and supported by laboratory evidence. Multiple clinical studies and meta-analyses show significant improvement in hair density with PRP in androgenetic alopecia, with a good safety profile. Outcomes vary based on preparation protocol, injection technique, and patient characteristics. PRP is best used as an add-on to DHT suppression and minoxidil rather than as a standalone treatment, adding a third growth factor pathway to a comprehensive protocol.